BLUETTI
11.7.2022 13:49:10 CEST | Business Wire | Press release
Do I have to be an Amazon Prime Member to take advantage of BLUETTI Prime Day deals?
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220710005073/en/
The short answer: nope. But if you’d like to grab the Prime Day sales only on Amazon , you’ll need to be an Amazon Prime Member.
BLUETTI confirms its annual shopping event - BLUETTI Prime Day date on July 5 - 15. To help you narrow things down, they've collected the best deals on their official website , from solar power stations, solar panels to various accessories worth your money.
The Best Prime Day Deals From BLUETTI
AC200P - The Most Popular 2kWh Solar Generator Now At The Lowest Price Ever - 1.699€ (was 1.999€)
Packed with a 2kW AC pure sine wave inverter, an enormous 2kWh capacity, and utilizing the most durable, safest LiFePO4 battery chemistry, the BLUETTI AC200P is undoubtedly the most cost-effective solar generator .
It can power all your needs from a household fridge to an 8.000 BTU portable air conditioner without breaking a sweat. Recharging by solar at a blistering speed up to 700W. You can juice up AC200P from zero to full in less than 4 hours with free, clean solar power alone!
AC200MAX - All-round Upgraded Power Beast - 2.099€ (was 2.399€)
With two expansion battery ports, the AC200MAX welcomes up to two BLUETTI B230 (2048Wh each) or B300 (3072Wh each) battery modules, allowing you to build on your system up to 8192Wh!
The AC200MAX allows up to 900W solar input and 400W via the AC wall charger, giving you a stunning 1300W total charging input to recharge it in less than 2 hours.
BLUETTI AC300 & B300 - Power Anything Imaginable - 3.899€ (was 4.299€)
Unlike any BLUETTI solar generator products, the AC300 has no built-in battery, bringing it unprecedented mobility and uniqueness. Every AC300 can accept up to 4 B300 (3072Wh each) battery modules, adding up to a groundbreaking 12288Wh capacity – Covering your whole family’s basic needs for DAYS during emergencies or power outages!
Time to plug into full-time solar life! BLUETTI AC300 is now capable of receiving 2400W of unrivaled solar charging input. The advanced MPPT controller lets you juice up a B300 (3072Wh) battery module as soon as 1,5hrs only with sunshine!
Other units highly recommended on BLUETTI UK & EU Prime Day 2022:
EB55 - 537Wh, 700W | Portable Solar Generator
- £549 (was £599);
EB70 - 716Wh, 1000W | Portable Power Station
- £649 (was £739);
B230 - 2048Wh LFP Expansion Battery
- £1399 (was £1499);
EP500Pro - 5100Wh, 3000W | Home Backup Power
- £5399 (was £5999)
AC200MAX & B230 - 4096Wh, 2200W | Portable Solar Generator
- £3199 (was £3499)
EB55 - 537Wh, 700W | Portable Solar Generator
- 599€ (was 649€);
EB70 - 716Wh, 1.000W | Portable Power Station
- 699€ (was 749€);
B230 - 2.048Wh LFP Expansion Battery
- 1.399€ (was 1.599€);
EP500Pro 5.100Wh, 3.000W | Home Backup Power
- 5.399€ (was 5.999€)
AC200MAX & 2/B230 & 3/SP200 - 6.144Wh, 2.200W | Bundles
- 6.394€ (was 8.249€)
About BLUETTI
With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220710005073/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom